Reversal of Chloroquine Resistance of Plasmodium vivax in Aotus Monkeys

Chloroquine-resistant (CQR) vivax malaria has emerged as a threat to the malaria elimination agenda. The objective of this study was to assess if a combination of chloroquine (CQ) and prochlorperazine was able to reverse CQ resistance of the AMRU-1 strain from Papua New Guinea in infected monkeys. F...

Full description

Saved in:
Bibliographic Details
Published inAntimicrobial agents and chemotherapy Vol. 62; no. 9
Main Authors Obaldia, 3rd, Nicanor, Milhous, Wilbur K, Kyle, Dennis E
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 01.09.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Chloroquine-resistant (CQR) vivax malaria has emerged as a threat to the malaria elimination agenda. The objective of this study was to assess if a combination of chloroquine (CQ) and prochlorperazine was able to reverse CQ resistance of the AMRU-1 strain from Papua New Guinea in infected monkeys. For this purpose, in two independent experimental drug efficacy trials, a total of 18 monkeys infected with blood obtained from donor animals were randomly assigned to treatment and control groups and orally administered CQ at 10 mg/kg or prochlorperazine at 20 mg/kg, alone or in combination, for five consecutive days. Reversal of CQR was achieved in animals that received the drug combination, whereas neither drug alone produced cures. This same drug combination reverses CQR in and could be an alternative for treatment in humans with chloroquine-resistant infections.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: Wilbur K. Milhous, Clemson University, College of Science, Clemson, South Carolina, USA.
Citation Obaldia N III, Milhous WK, Kyle DE. 2018. Reversal of chloroquine resistance of Plasmodium vivax in Aotus monkeys. Antimicrob Agents Chemother 62:e00582-18. https://doi.org/10.1128/AAC.00582-18.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.00582-18